Announcements Trials

Browse Landscape

Phase

Status

Completed 3 Unknown 1 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 1 Renal Insufficiency 1 Paraproteinemias 1 Neoplasms, Plasma Cell 1 Neoplasms by Histologic Type 1 Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Hematologic Diseases 1 Blood Protein Disorders 1

Interventions

Cyclophosphamide 27 Rituximab 20 Etoposide 14 Cytarabine 13 Melphalan 11 Vincristine 10 fludarabine 9 Prednisone 9 Doxorubicin 9 Busulfan 8 Peripheral Blood Stem Cell Transplantation 7 Radiotherapy 6 Filgrastim 6 Cyclosporine 6 Bendamustine Hydrochloride 6 fludarabine phosphate 5 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5 Mycophenolic Acid 5 Cisplatin 5 tositumomab I-131 4 ibritumomab tiuxetan 4 Ifosfamide 4 Dexamethasone 4 Carmustine 4 relmacabtagene autoleucel 3 Thiotepa 3 Indium 3 Immunotherapy, Adoptive 3 Gemcitabine 3 Drug Therapy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Lymphoma, Non-Hodgkin × Diphenhydramine × Clear all

NCT00324467 2021-07-22

LYTPET

British Columbia Cancer Agency

Phase 2 Unknown

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡